Cargando…

Acquired Resistance to Immune Checkpoint Blockade Therapies

Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of patients who initially respond to ICBT subsequently develop resistance. Comprehensive genomic analysis of samples from recent clinical trials and pre-clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Xianda, Wangmo, Dechen, Robertson, Matthew, Subramanian, Subbaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280955/ https://www.ncbi.nlm.nih.gov/pubmed/32380703 http://dx.doi.org/10.3390/cancers12051161

Ejemplares similares

Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer
por: Gates, Travis J, et al.
Publicado: (2023)

Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer
por: Gates, Travis J., et al.
Publicado: (2023)

Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors
por: Zhao, Xianda, et al.
Publicado: (2020)

ACKR4 in Tumor Cells Regulates Dendritic Cell Migration to Tumor-Draining Lymph Nodes and T-Cell Priming
por: Wangmo, Dechen, et al.
Publicado: (2021)

Cancer Immunology and Immunotherapies: Mechanisms That Affect Antitumor Immune Response and Treatment Resistance
por: Zhao, Xianda, et al.
Publicado: (2021)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
por: Boyero, Laura, et al.
Publicado: (2020)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Tumor location impacts immune response in mouse models of colon cancer
por: Zhao, Xianda, et al.
Publicado: (2017)

Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications
por: Zhao, Xianda, et al.
Publicado: (2023)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
por: Cremolini, Chiara, et al.
Publicado: (2021)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
por: Subramanian, Madhav, et al.
Publicado: (2023)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
por: Wang, Bin, et al.
Publicado: (2023)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade
por: Lotsberg, Maria L., et al.
Publicado: (2020)

Combinations using checkpoint blockade to overcome resistance
por: Morganti, Stefania, et al.
Publicado: (2020)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
por: Ho, Rachel L. Y., et al.
Publicado: (2021)

Gastric Cancer in the Era of Immune Checkpoint Blockade
por: Figueroa-Protti, Lucía, et al.
Publicado: (2019)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016)

Metabolic predictors of response to immune checkpoint blockade therapy
por: Shorer, Ofir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qn9kdqll3kss0hq4chk2mema39